Correct, but he's also said something to the effect about a DX split (about a 100 times) and has been very adamant about it lately. If we don't have a product or want to keep this product then why go through the trouble of hiring the people to run one? Just for show? I doubt it. I see us selling Nuropro. Nuropro has been quiet as of late. Once Lympro is up and running generating revenue then Nurpro automatically comes with built in expectations and value making it easier to sell for more. That's my thinking.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links